Mefloquine for preventing malaria during travel to endemic areas (Review)

by M. Tickell-Painter, N. Maayan, R. Saunders et al.
Cochrane Database of Systematic Reviews, 2017, Issue 10

338 pp. 3.7 MB
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006491.pub4/epdf

Mefloquine has been linked with psychological side effects since its introduction in the 1980s, and the Cochrane review now brings together over 50 randomized and non-randomized studies, enrolling over 1,000,000 people, and compares mefloquine with alternatives in common use. “There is no doubt that mefloquine does cause more sleeplessness, abnormal dreams, anxiety and depressed mood than the alternatives” says one of the authors, “but the review clarifies that these are symptoms reported by people taking mefloquine and not formal psychiatric diagnoses. Serious side effects with mefloquine seem to be rare, less than 1% of users, and increases in formal diagnoses of depression and psychosis have not been seen in people returning from travel in any of the large database studies.”

(Visited 10 times, 1 visits today)
This entry was posted in Essential Medicines, General, Malaria. Bookmark the permalink.